194 related articles for article (PubMed ID: 33146913)
1. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort.
Garg T; McMullen CK; Leo MC; O'Keeffe-Rosetti MC; Weinmann S; Nielsen ME
Cancer; 2021 Feb; 127(4):520-527. PubMed ID: 33146913
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
[TBL] [Abstract][Full Text] [Related]
3. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients.
Lu M; Chen S; Zhou Q; Wang L; Peng T; Wang G
Medicine (Baltimore); 2019 Jul; 98(28):e16426. PubMed ID: 31305463
[TBL] [Abstract][Full Text] [Related]
4. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort.
Ritch CR; Velasquez MC; Kwon D; Becerra MF; Soodana-Prakash N; Atluri VS; Almengo K; Alameddine M; Kineish O; Kava BR; Punnen S; Parekh DJ; Gonzalgo ML
J Urol; 2020 Mar; 203(3):505-511. PubMed ID: 31609178
[TBL] [Abstract][Full Text] [Related]
5. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.
Bree KK; Shan Y; Hensley PJ; Lobo N; Hu C; Tyler DS; Chamie K; Kamat AM; Williams SB
JAMA Netw Open; 2022 Mar; 5(3):e223050. PubMed ID: 35302627
[TBL] [Abstract][Full Text] [Related]
6. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
7. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
8. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.
Simon M; Bosset PO; Rouanne M; Benhamou S; Radulescu C; Molinié V; Neuzillet Y; Paoletti X; Lebret T
PLoS One; 2019; 14(2):e0211721. PubMed ID: 30811419
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
[TBL] [Abstract][Full Text] [Related]
10. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
[TBL] [Abstract][Full Text] [Related]
11. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
[TBL] [Abstract][Full Text] [Related]
12. Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults.
Garg T; Young AJ; O'Keeffe-Rosetti M; McMullen CK; Nielsen ME; Murphy TE; Kirchner HL
Urol Oncol; 2020 Sep; 38(9):737.e17-737.e23. PubMed ID: 32409197
[TBL] [Abstract][Full Text] [Related]
13. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
[TBL] [Abstract][Full Text] [Related]
15. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
16. Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort.
Sharma V; Chamie K; Schoenberg M; Lee VS; Fero K; Lec P; Munneke JR; Aaronson DS; Kushi LH; Quesenberry CP; Tang L; Kwan ML
Urology; 2023 Mar; 173():134-141. PubMed ID: 36574911
[TBL] [Abstract][Full Text] [Related]
17. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
18. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.
Millán-Rodríguez F; Chéchile-Toniolo G; Salvador-Bayarri J; Palou J; Algaba F; Vicente-Rodríguez J
J Urol; 2000 Sep; 164(3 Pt 1):680-4. PubMed ID: 10954628
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
